Citations

Showing 10 of 108083 citations.

Tumor growth is attenuated in eosinophil-deficient mouse models (165.41)
Taranova, Anna G. , Ochkur, Sergei I. , Protheroe, Cheryl, Condjella, Rachel, Colbert, Dana, Zellner, Katie R. , McGarry, Michael P. , Lee, Nancy Y. , Jacobsen, Elizabeth A. , Lee, James

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 186 | Issue: 1_Supplement | Pages: 165.41-165.41

10.4049/jimmunol.186.supp.165.41 Get It

Abstract Eosinophil infiltration into tumors has been associated with positive and negative growth human cancers and in mouse models of tumorigenesis. Our previous studies have shown that eosinophils infiltrate tumors and differentially accumulate in the necrotic and capsule regions of tumors. Using various eosinophil-deficient mouse models, we demonstrate that in the absence of eosinophils tumor growth is attenuated. Methods: Tumor growth kinetics were assessed using a B16F10 melanoma subcutaneous cell injection model. Eosinophil chemotaxis was assessed using an ex vivo transwell insert assay system. We compared tumor growth in wild type animals vs. various eosinophil-deficient mouse models that are transgenic line of mice (PHIL) and MBP-/-/EPO-/- double knockout mice that are deficient in eosinophil-specific proteins (major basic protein (MBP) and eosinophil peroxide (EPO)) resulting in a blockade of eosinophilpoiesis. Conclusions: The migration of eosinophils was inhibited through blocking the sphingosine-1-phosphate pathway, suggesting recruitment and accumulation is primarily an inflammatory response. Tumor growth was decreased by ~40-60% in PHIL and in MBP-/-/EPO-/- double knockout mice relative to tumors in wild type animals. In addition, EPO-/- mice, and not MBP-/-mice, replicate this ~40% reduction in tumor size implicating a significant role for EPO in tumor growth kinetics. These data suggest eosinophils respond to inflammatory mediators and mediate augment tumor growth.
Adoptive transfer of multiple CTL clones limits antigen gene loss and tumor escape (156.22)
Kaluza, Karen M., Thompson, Jill, Vile, Richard G.

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 186 | Issue: 1_Supplement | Pages: 156.22-156.22

10.4049/jimmunol.186.supp.156.22 Get It

Abstract We study mechanisms of tumor escape from adoptive therapy in the mouse melanoma model B16ova. In this model, transfer of OT-I T cells can significantly prolong the survival of mice. However, intense OT-I pressure promotes tumor cell genomic instability, and most mice eventually develop recurrent ova gene-loss tumors. We hypothesized that simultaneous transfer of two CTL clones would limit tumor recurrence by preventing the selection of single gene-loss cells. To accomplish this, we co-transferred OT-I T cells and Pmel T cells. Co-transfer three days following tumor challenge prevented tumor growth, while neither clone alone could. And in mice with established tumors, co-transfer provided significantly better therapy than either clone alone. This improvement was due to both fewer tumors recurring and the delayed appearance of those that did recur. Additionally, we found that recurrent tumors from mice treated with co-transfer continued to express both target antigens, and the mice maintained both T cell populations. We therefore hypothesized that it should be possible to exploit those cells to further prolong the survival of mice. We used cyclophosphamide to stimulate reactivation of the immune system in mice with recurrent tumors and found that this supplemental therapy significantly prolonged the lives of only those mice which had previously received co-transfer. Overall, our results reveal several benefits of targeting multiple tumor antigens.
CD4+CD25+FOXP3+ regulatory T cells and association with survival in epithelial ovarian cancer (74.9)
Oberg, Ann L. , Hartmann, Lynn C. , Kalli, Kimberly R., Goode, Ellen L. , Knutson, Keith L. , Preston, Claudia C. , Maurer, Matthew J. , Knutson, Keith L.

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 188 | Issue: 1_Supplement | Pages: 74.9-74.9

10.4049/jimmunol.188.supp.74.9 Get It

Abstract Ovarian cancer is an immune reactive tumor with a complex suppressive network that blunts immune eradication. One putative pathway of evasion may be recruitment of CD4 regulatory T cells (Treg) into the tumor microenvironment. This study investigated the association of tumor infiltrating Tregs in ovarian cancer patients with poor survival. Methods: Immunofluorescence of intraepithelial CD4+CD25+FOXP3+ Tregs, CD3+ and CD8+ cells was performed in tumors of 52 ovarian cancer patients. Average and maximum count of cells were associated with survival via Cox regression models and summarized with hazard ratios (HR) and 95% confidence intervals (CIs). Results: The maximum counts of Tregs in these patients suggests an association between higher number of Tregs and poor clinical outcome (HR=1.48, CI=0.97, 2.28), although not statistically significant (p=0.07). Moreover, presence of high CD8/Treg ratio (HR=0.7, CI=0.53, 0.91; p=0.008) as well as high CD8/CD4 ratio (HR=0.76, CI=0.57, 1.0; p=0.05) appear to be associated with good outcome. The CD3 lymphocyte count was not associated with survival (HR=0.9, CI=0.66, 1.24; p=0.52). Conclusion: Although the present pilot study was conducted with a limited number of patients, our data suggests that higher numbers of infiltrating Tregs might be associated with poor survival and low CD8/Treg ratio may be correlated with improved survival in patients with epithelial ovarian carcinoma. We plan to confirm these results in a larger set of patients.
Identification and characterization of macrophage regulatory cells (Mac-regs) with immunoregulatory properties (89.38)
Manrique, Soraya Zorro, Mirza, Noweeda, Smith, Shannon E., Lustgarten, Joseph, Duque‐Correa, Maria A. , Dominguez, Ana Lucía , Hoelzinger, Dominique B.

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 182 | Issue: Supplement_1 | Pages: 89.38-89.38

10.4049/jimmunol.182.supp.89.38 Get It

Abstract Macrophages with suppressive characteristics such as Tumor associated macrophages or Myeloid derived suppressor cells have been defined showing regulatory function under inflammatory or polarizing conditions. Until now, there are no reports indicating that under normal, non-inflammatory or non-polarizing conditions, macrophages could have immunoregulatory functions. Utilizing knock-in Foxp3-GFP mice, we identified a new population of Foxp3 positive cells that were CD11b+F4/80+ cells. These cells were observed in spleen, lymph nodes, bone marrow and thymus. Similar to Tregs, the CD11b+F4/80+Foxp3+ macrophages inhibited T cell proliferation, whereas Foxp3neg macrophages did not. The Foxp3neg macrophages could be converted to express Foxp3. These induced-CD11b+F4/80+Foxp3+ cells displayed inhibitory properties similar to natural Foxp3pos macrophages. Based on the immunoregulatory properties of these cells, we termed them Macrophage regulatory cells (Mac-regs). These Mac-regs express CD68hiF4/80hiCTLA4hiGITRhiIL-4Rhi. Interestingly, GR-1 is not a differentiation marker. The cytokine, chemokine, growth factor and genomic profiles of Mac-regs are different compared to CD11b+F4/80+Foxp3-cells. For the first time, we demonstrated the occurrence of a natural population of macrophages displaying regulatory function which may contribute to the homeostatic balance of the immune system. This research was supported by Grants from the NIH and AFAR.
Therapeutic use of proteasome inhibitors in bacterial superantigen- and LPS-induced acute systemic inflammatory response syndromes (93.13)
Rajagopalan, Govindarajan , Tilahun, Ashenafi Y. , David, Chella S.

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 182 | Issue: Supplement_1 | Pages: 93.13-93.13

10.4049/jimmunol.182.supp.93.13 Get It

Abstract Bacterial superantigen-induced toxic shock syndrome (TSS) and sepsis are characterized by a profound systemic inflammatory response. Given the important role of NF¿B pathway in inflammation, we investigated whether a clinically approved proteasome inhibitor, Bortezomib, capable of inhibiting NF¿B pathway, be of therapeutic use in such conditions using HLA class II transgenic mice. Bortezomib significantly blocked staphylococcal enterotoxin B (SEB)-induced T cell activation and cytokine production in vitro. In SEB-induced TSS, in vivo administration of Bortezomib significantly reduced serum levels of several pro-inflammatory cytokines and chemokines. Nevertheless, 100% of SEB challenged mice treated with Bortezomib succumbed to TSS, and Bortezomib sensitized mice to TSS at concentrations of SEB which are otherwise non-lethal (i.e., as low as 2 μg/mouse), even when administered 24 hours after exposure to SEB. Sensitization to TSS by Bortezomib was not due to the pro-apoptotic effects of Bortezomib. Serum biochemical parameters and histopathological findings suggested acute liver failure as the possible cause of mortality. In sepsis model, whereas LPS alone (10 μg/mouse) was seldom lethal, it was uniformly lethal when administered along with Bortezomib. In conclusion, Bortezomib sensitizes mice to certain acute systemic inflammatory diseases. Supported by R01AI068741 and AI 72211
Retargeting IgM Antibodies with Different Specificities to a Common Cell Type Reveals Shared Mechanisms Regulating Cellular Activation (91.12)
Keenan, Thomas D, Radhakrishnan, Suresh , Bell, Michael V., Pease, Larry R. , Keenan, Thomas D, Bell, Michael, Barry, Michael A

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 182 | Issue: 1_Supplement | Pages: 91.12-91.12

10.4049/jimmunol.182.supp.91.12 Get It

Abstract IgM antibodies, as multivalent ligands, have the capacity to activate cells differentially by cross-linking targeted cell surface signaling molecules. For example, hIgM12 (B7DC Xab) activates dendritic cells (DCs), leading to potent immunomodulation, while hIgM22 binds glial cells and causes remyelination in mouse models of multiple sclerosis. Both antibodies activate common signaling intermediates in their respective cellular targets suggesting a common mechanism of action. Elucidation of these shared mechanisms became possible by targeting both antibodies to a common cell type. Our previous studies demonstrate that B7-DC expression is required to activate downstream signaling in DCs by hIgM12. We utilized a phage display system to identify 7mer peptides bound by each IgM and expressed each peptide attached to a surrogate cell surface carrier on retrovirally tranduced bone marrow-derived DCs from B7-DC -/- mice. Transduced cells were treated with hIgM12, hIgM22 or anti-carrier IgM, and subsequent activity was compared against B7-DC +/+ DCs or B7-DC-reconstituted B7-DC -/- DCs. DC activation by each IgM was specific to expression of their conjugate peptide construct. Activation by hIgM22 was indistinguishable from activation by hIgM12, while anti-carrier IgM caused no activation. This indicates that while their target specificity differs, once bound these IgMs activate cells via common mechanisms.
T cell-intrinsic B7-homolog-1 (B7-H1) regulates effector CD8 T cell survival and memory cell generation (83.13)
Pulko, Vesna, Harris, Kimberley J., Dong, Haidong , Liu, Xin , Harris, Kimberley

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 182 | Issue: Supplement_1 | Pages: 83.13-83.13

10.4049/jimmunol.182.supp.83.13 Get It

Abstract B7 homolog-1 ( B7-H1) expressed by antigen-presenting cells or tumor cells is a negative regulator of T cell responses, however its function on T cells is not clear. Here we show that B7-H1 was upregulated in CD8 T cells during immunization and its expression was maintained on memory CD8 T cells. Although B7-H1 deficient naïve CD8 T cells responded normally to antigen stimulation and underwent normal antigen-independent homeostatic proliferation, the maximal expansion of CD8 T cells was blocked due to their high susceptibility to apoptosis. B7-H1-deficient effector CD8 T cells showed weaker effector function and cytotoxicity against tumor cells compared to that of normal CD8 T cells. Once activated, B7-H1-deficient CD8 T cells generated less memory T cells. This effect was independent of the primary expansion of the antigen-specific CD8 T cell population. Our results revealed previously unknown function of B7-H1 on CD8 T cells in mediating survival and differentiation of effector CD8 T cells into memory T cells.
Lipoteichoic acid synergizes with ATP to activate dendritic cells for a pro-inflammatory TH17-polarizing phenotype (133.22)
Paustian, Christopher, Johnson, Terrence D., Czerniecki, Brian J. , Shu, Suyu, Cohen, Peter A. , Koski, Gary K.

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 182 | Issue: 1_Supplement | Pages: 133.22-133.22

10.4049/jimmunol.182.supp.133.22 Get It

Abstract Stimulation of dendritic cells (DCs) by exogenous danger signals such as single Toll-like receptor (TLR) ligands results in generalized DC activation. Recently, Napolitani and co-workers showed select TLR ligand pairings induced a more specialized DC activation program including enhanced IL-12 p70 secretion and the capacity to polarize CD4 T cells into IFN-γ-secreting Th1 cells. We therefore examined the effect of pairing an exogenous TLR2 ligand (lipoteichoic acid) with an endogenous danger signal, ATP, which is found in high extracellular concentrations in damaged tissues, malignant tumors, and possibly other pathophysiological settings. ATP added to LTA modified somewhat the expression of common DC activation markers, but primarily induced a distinct pattern of cytokines with greatly enhanced levels of both IL-23 and IL-1β, while TNF, IL-10 and IL-6 remained mostly unchanged. IL-12 was not produced. These DC induced a Th17 response when stimulating allogeneic T cells in a manner partially dependent on IL-1β. These studies show that pairing of endogenous and exogenous danger signals can induce a specialized DC activation program that may have important physiological implications.
The Role of CD8+ CD40L+ T Cells in the Formation of Germinal Centers in Rheumatoid Synovitis
Wagner, Ulf , Kurtin, Paul J. , Wahner, Andrea E., Marc, Brackertz, Weyand, Cornelia M. , Berry, Daniel J. , Goronzy, Jörg J.

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 161 | Issue: 11 | Pages: 6390-6397

10.4049/jimmunol.161.11.6390 Get It

Abstract In rheumatoid synovitis, lymphocytes can be arranged in follicular structures resembling secondary lymphoid follicles. To understand the organizing principles of this ectopic lymphoid tissue, the cellular components contributing to synovial follicles were examined. In 9 of 24 synovial tissue biopsies, lymphoid aggregates were found consisting of CD4+ T cells and CD20+ B cells. In four of the nine patients, the follicular centers were occupied by CD23+ CD21+ cellular networks representing follicular dendritic cells involved in germinal center reactions. In five patients, CD23+ cells were absent from the centers of the aggregates, suggesting that fully developed germinal centers are generated in only a subset of patients. To identify factors involved in the regulation of the synovial microarchitecture, cell populations contributing to the follicles were quantified by digital image analysis of immunostained tissue and by flow cytometry of tissue-derived lymphocytes. Proportions of CD4+, CD20+, and CD68+ cell subsets were surprisingly invariant, irrespective of the presence or absence of CD23+ follicular dendritic cells. Instead, tissue biopsies with CD23+ germinal center-like regions could be distinguished from those with CD23− T cell-B cell aggregates by a fourfold increase in the frequency of tissue-infiltrating CD8+ T cells, a fraction of which expressed CD40 ligand (CD40L). The data suggest a previously unsuspected role of CD8+ lymphocytes in modulating germinal center formation and raise the possibility that CD8+ CD40L+ T cells are involved in aggravating pathologic immune responses in rheumatoid synovitis.
Aging is associated with an increase in regulatory T cells, MCP-1 and RANTES (179.13)
Nevala, Wendy K. , Dronca, Roxana , Leontovich, Alexey A. , Markovic, Svetomir, Mansfield, Aaron S. , Markovic, Svetomir N.

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 188 | Issue: 1_Supplement | Pages: 179.13-179.13

10.4049/jimmunol.188.supp.179.13 Get It

Abstract We have observed Th2 polarization in patients with metastatic malignant melanoma. We hypothesized that changes in the immune system with age may parallel changes we have seen in patients with cancer. We analyzed the peripheral blood of 389 healthy blood donors. We profiled T cell subsets in 389 of the subjects, and antigen-specific tetramers for CMV, influenza and MART-1 in 58 of the subjects. We used a cytokine multiplex to analyze 42 cytokines in 95 of the subjects. We observed significant increases in CD4+ Th2 cells, and decreases in CD3+ T cells, cytotoxic T cells and helper T cells with age. There were fewer CMV-, influenza- and MART-1- specific naïve and CD8+ T cells with age. There were also significant increases in MCP-1 and RANTES with age. We observed differences between males in females in their cytokine profiles in their 20-40’s but not in their 50-60’s. In summary, we have found that aging is associated with an increase in CD4+ Th2 cells and concomitant decreases in total T cell count, cytotoxic T cells and helper T cells. Furthermore, aging is associated with increases in MCP-1 and RANTES. Females had different cytokine profiles than males before menopause, but not after.